Kuzuya T, et al. - Researchers explored prognostic factors related to post-progression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib not eligible for second-line treatment with regorafenib. Study participants were patients with radiological confirmation of progressive disease (PD). The median PPS of 6.1 months was reported. Findings demonstrated the possible utility of an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0, the absence of macrovascular invasion (MVI), and time to progression (TTP) ≥4 months at first radiological confirmation of PD for predicting good PPS in patients with advanced HCC who did not meet the eligibility criteria for the RESORCE trial.